Salute e Benessere

Changes to the Nomination Committee's proposal to the Annual General Meeting…

Michael Löfman Michael Löfman Michael Löfman has a Master of Science (MSc) in Economics and Business Administration from the University of Uppsala (1989) and has extensive experience working in the financial sector with valuation and market research. He started his career as an investment analyst with different brokers and asset managers and has held various positions with Swedish Credit Insurance, Swedbank Markets, Trygg-Hansa Asset Management, and SEB Investment Management. 2004-2014...
PR Newswire
22/05/2023

Telesis Bio Announces First Commercial Shipment of BioXp® Select DNA Cloning Kit

New Kit Enables Automation of DNA Cloning on the BioXp® System Beginning from Linear DNA, Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Molecular Biology Workstation ®Select DNA Cloning kit. TheBioXp ®Select DNA Cloning kitenables on-demand and automated assembly of DNA fragments via Gibson Assembly ®or Golden Gate assembly cloning methods beginning from the customer's linear DNA. The continued expansion of automation capabilities of the BioXp ®...
Nasdaq GlobeNewswire
22/05/2023

Global Opportunities in Orthopedic Prosthetic Market Size Will Reach Over US$…

Orthopedic Prosthetic Market: Overview Orthopedic Prosthetic Market: Overview Artificially created body parts that are used as substitutes for actual body parts are called orthopedic prosthetic devices. The main goal of using these devices is to ensure that the substituted body part functions normally thus assisting in improving the quality of life of the patients undergoing these procedures. People who have undergone orthopedic surgery or suffer from congenital abnormalities along with...
PR Newswire
22/05/2023

Rehabilitation Equipment Market to Grow Significantly by 2029- Brandessence…

Key Takeaways Key Takeaways The Rehabilitation Equipment Market is anticipated to garner significant returns over the estimated timeline of 2022-2029. Get Sample of Report@https://www.aimarketreport.com/downloadSample/PostId/1301 Elaborating the key trends and dynamics of Rehabilitation Equipment Market Growing occurrence of injuries caused by road accidents, sports, and other incidents is one of the primary factors spurring the growth of this market. Furthermore,...
PR Newswire
22/05/2023

Sickle Cell Disease Market to Observe Impressive Growth, Predicts DelveInsight |…

Key Takeaways from the Sickle Cell Disease Market Report Key Takeaways from the Sickle Cell Disease Market Report Discover which therapies are expected to grab the major sickle cell disease market share @Sickle Cell Disease Market Report Sickle Cell Disease Overview Sickle cell disease is a group of inherited red blood cell illnesses characterized by a structural anomaly of hemoglobin called sickle hemoglobin (HbS), which encodes hemoglobin subunit. Sickle cell disease is...
PR Newswire
22/05/2023

Sports Medicine Market to Grow Exponentially by 2029- Brandessence Market…

Key Takeaways Key Takeaways The Sports Medicine Market is anticipated to accrue notable returns over the assessment timeline of 2022-2029. Get Sample of Report@https://www.aimarketreport.com/downloadSample/PostId/1299 Elaborating the key trends and dynamics of Sports Medicine Market Rising number of sports enthusiasts, growing instances of sports-based injuries, and increased healthcare expenditure are primarily augmenting the outlook of this marketplace. Also, surging...
PR Newswire
22/05/2023

Dental Digital X-ray Market to Reach $7.2 Billion, Globally, by 2032 at 8.5%…

Download Free Sample Report: https://www.alliedmarketresearch.com/request-sample/3736 Download Free Sample Report :https://www.alliedmarketresearch.com/request-sample/3736 Prime determinants of growth Increase in prevalence of dental diseases, surge in geriatric population, various technological advancements in dental digital X-ray systems that have significantly improved the accuracy, speed, & safety of dental X-ray system and rise in adoption of digital X-ray system over...
PR Newswire
22/05/2023

Novo Nordisk A/S: Oral semaglutide 50 mg achieved 15.1% weight loss (17.4% if…

Bagsværd, Denmark, 22 May 2023– Novo Nordisk today announced headline results from OASIS 1, a phase 3a trial in the global OASIS programme. OASIS 1 is a 68-week, efficacy and safety trial comparing once-daily oral semaglutide 50 mg for weight management to placebo in 667 adults with obesity or overweight with one or more comorbidities. Both treatment arms were in conjunction with lifestyle intervention. The trial achieved its primary endpoint by demonstrating a statistically significant...
Nasdaq GlobeNewswire
22/05/2023

CSafe Providing Sustainable Thermal Protection for Vyjuvek Gene Therapy from…

The Vyjukek supply chain is further optimized by utilizing CSafe's Retest & Reuse program. This approach features reusable shippers that maintain the highest level of thermal performance. When customers participate in CSafe's reuse program, our highly qualified team inspects, cleans and thermally requalifies the insulation and shippers to assure thermal integrity prior to reuse. This fully managed, end-to-end solution reduces unnecessary landfill waste and is an efficient, effective, and…
PR Newswire
22/05/2023

BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to…

BBS-Bioactive Bone Substitutes Plc, Company announcement, 22 May 2023 4:00 p.m.BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd BBS-Bioactive Bone Substitutes Plc (“BBS” or the "Company") has received a request by Riverfort Global Opportunities PCC Ltd to convert a proportion of EUR 25,000 of the convertible notes into Company shares at a conversion price of EUR 0.755460 per…
Nasdaq GlobeNewswire
22/05/2023

Fermion to Release Updated Data At 2023 BIO International Convention

Fermion's Chief Executive Officer, Dr. Deco Deng, stated, "through our commitment to innovative drug development empowered by Fermion Drug Studio AI Platform, we are delighted to showcase multiple programs at this year's BIO and share our progress with fellow biotech and pharmaceutical companies as we continue to advance these programs towards our ultimate goal of improving patient outcomes." Fermion's Chief Executive Officer, Dr. Deco Deng, stated, "through our commitment to…
PR Newswire
22/05/2023

FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients

XBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis Treatment The randomized, double-blind, placebo-controlled, trial will examine the effectiveness of Natrunix to treat rheumatoid arthritis compared to placebo in subjects already receiving stable but inadequate treatment with methotrexate (MTX). A total of 210 patients will be randomly distributed in equal numbers into three groups: including two different Natrunix dosages and a placebo group. Change in disease...
Nasdaq GlobeNewswire
22/05/2023

Philips and Vanderbilt University Medical Center unite to define roadmap for…

Amsterdam, the Netherlands and Nashville, TN, USA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Vanderbilt University Medical Center (VUMC), home to the top-ranked adult and pediatric hospitals in the Southeastern U.S., today announced a collaboration that aims to reduce the health system's carbon footprint while determining a blueprint to guide industry efforts. The project is with the radiology department, where efforts will focus on measuring...
Nasdaq GlobeNewswire
22/05/2023

Vistin Pharma ASA: Minutes from the Annual General Meeting 2023

Vistin Pharma ASA (OSE: VISTIN): Please find attached the minutes from the Annual General Meeting held today, on the 22 May 2023. All matters were resolved as proposed in the call for the Annual General Meeting.For further information, please contact:Alexander Karlsen CFO +47 97 05 36 21 alexander.karlsen@vistin.com This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachment Minutes from AGM 22 may...
Nasdaq GlobeNewswire
22/05/2023

Pierre Fabre announces start of EU marketing authorization application procedure…

The submission also includes clinical data from the study URO-901-1001, a randomized, Phase 1, double-blind, placebo-controlled, parallel-group study in subjects with OAB, designed to study the effect of Vibegron (at a dose of 75 mg or placebo for 28 days) at steady state on ambulatory blood pressure (BP) and heart rate (HR). Results from this study confirm that Vibegron 75 mg had no statistically significant or clinically meaningful effects on BP or HR in patients with symptoms of OAB. The...
PR Newswire
22/05/2023

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 22 May 2023– On 9 May 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under the...
Nasdaq GlobeNewswire
22/05/2023

Proem Behavioral Health and Dr. David V. Sheehan Issue Joint Statement

Logo - https://mma.prnewswire.com/media/1959221/4024057/Proem_Behavioral_Health_Logo.jpg Logo - https://mma.prnewswire.com/media/1959221/4024057/Proem_Behavioral_Health_Logo.jpg View original content: https://www.prnewswire.co.uk/news-releases/proem-behavioral-health-and-dr-david-v-sheehan-issue-joint-statement-301826138.html
PR Newswire
22/05/2023

New urban health 'accelerator' aims to transform cardiovascular population…

Projections based on initial CARDIO4Cities programs in São Paulo (Brazil), Dakar (Senegal) and Ulaanbaatar (Mongolia), published in PLOS Global Public Health2, revealed that CARDIO4Cities was highly cost-effective, increased blood pressure controls by three times or more, and averted up to 13% of strokes and 12% of heart attacks within one to two years of implementation. Projections based on initial CARDIO4Cities programs in SãoPaulo (Brazil),Dakar( Senegal ) and Ulaanbaatar ( Mongolia...
PR Newswire
22/05/2023

Endotronix Extends Positive Outcomes with 12-month Data Release from the SIRONA…

"Adding to a robust foundation of clinical evidence supporting the use of Cordella, the 12-month SIRONA 2 data further validates the benefit of PA pressure-guided therapy to improve patient outcomes for NYHA class III patients," stated Prof. Aßmus. "Cordella's comprehensive approach consists of PA pressure data plus non-invasive data, including blood pressure, weight, and heart rate, which enables my team to efficiently titrate key HF medications remotely and help patients feel…
PR Newswire
22/05/2023

Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for…

BOSTON and LONDON, May22, 2023(GLOBE NEWSWIRE) --Centessa Pharmaceuticals plc(Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SerpinPC, an investigational novel inhibitor of activated protein C (APC) being developed for the treatment of hemophilia B, with or without inhibitors. "We are...
Nasdaq GlobeNewswire
22/05/2023

Grünenthal's resiniferatoxin receives Breakthrough Therapy Designation from U.S…

Resiniferatoxin is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist with a well-validated mechanism of action. The discovery of a number of receptors, including TRPV1, and their role in the perception of temperature and touch was awarded the 2021 Nobel Prize in Physiology or Medicine. If approved, resiniferatoxin has the potential to become a meaningful non-opioid treatment option providing long-lasting pain relief and functional improvement of the affected joint…
PR Newswire
22/05/2023

Music Therapy Market to Expand at 9.4% CAGR till 2031| Growth Market Reports

Download PDF Sample here: https://growthmarketreports.com/request-sample/4982 Download PDF Sample here: https://growthmarketreports.com/request-sample/4982 The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include type, application, end-user, and competitor analysis. This report also includes a complete analysis...
PR Newswire
22/05/2023

Emmanuel Butstraen appointed as President of Perfumery & Beauty at dsm-firmenich

Prior to his appointment as Chief Integration Officer, Emmanuel served as the President of Taste & Beyond at Firmenich since 2018. Under his leadership, the business underwent a transformative journey, becoming a global innovation partner of choice. He also brings extensive experience in the personal care sector, having previously served as the President of Solvay's Novecare global business unit. Before that, he spent 17 years at BASF, where he held the position of Strategy Senior Vice…
PR Newswire
22/05/2023

Pharmaceutical Filtration Market to be Worth $21.96 Billion by 2030: Grand View…

Read 150 page market research report, "Pharmaceutical Filtration Market Size, Share & Trends Analysis Report By Product (Membrane Filters, Pre-filters & Depth Media), By Technique, By Type, By Application, By Scale Of Operation, By Region, And Segment Forecasts, 2023 - 2030", published by Grand View Research. Read 150 page market research report, " Pharmaceutical Filtration Market Size, Share & Trends Analysis Report By Product (Membrane Filters, Pre-filters &…
PR Newswire
22/05/2023
Altri  Comunicati